Showing 1 - 8 results of 8 for search 'Verena Ramirez Campos', query time: 0.03s Refine Results
  1. 1
    Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

    Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies by Peter McAllister, Joshua M. Cohen, Verena Ramirez Campos, Xiaoping Ning, Lindsay Janka, Steve Barash

    Published 2022-08-01
    Get full text
    Article
  2. 2
    Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial

    Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlle... by Egilius L. H. Spierings, Mikko Kärppä, Xiaoping Ning, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang, Uwe Reuter

    Published 2021-04-01
    Get full text
    Article
  3. 3
    Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

    Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study by Dawn C. Buse, Sanjay K. Gandhi, Joshua M. Cohen, Verena Ramirez-Campos, Blaine Cloud, Ronghua Yang, Robert P. Cowan

    Published 2020-09-01
    Get full text
    Article
  4. 4
    Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine

    Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and pro... by Kimberly D. Mackenzie, Mario Ortega, Yoel Kessler, Verena Ramirez Campos, Lynda J. Krasenbaum, Karen Carr, Xiaoping Ning, Jennifer Stratton

    Published 2022-11-01
    Get full text
    Article
  5. 5
    Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

    Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 m... by Messoud Ashina, Joshua M. Cohen, Maja Galic, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Yoel Kessler, Lindsay Janka, Hans-Christoph Diener

    Published 2021-07-01
    Get full text
    Article
  6. 6
    Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

    Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study by Antoinette MaassenVanDenBrink, Gisela M. Terwindt, Joshua M. Cohen, Steve Barash, Verena Ramirez Campos, Maja Galic, Xiaoping Ning, Mikko Kärppä

    Published 2021-12-01
    Get full text
    Article
  7. 7
    Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

    Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, pla... by Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl

    Published 2022-05-01
    Get full text
    Article
  8. 8
    Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

    Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-control... by Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl

    Published 2021-11-01
    Get full text
    Article

Search Tools: